

## FIRST TIME GENERIC APPROVAL

<b>Brand Name</b>	Apriso™
<b>Generic Name</b>	mesalamine
<b>Drug Manufacturer</b>	Sun Pharmaceutical Industries, Inc.

### New Drug Approval

#### TYPE OF CLINICAL UPDATE

First Time Generic

#### FDA APPROVAL DATE

May 11, 2022

#### LAUNCH DATE

May 17, 2022

#### REVIEW DESIGNATION

Standard

#### TYPE OF REVIEW

Abbreviated New Drug Application (ANDA): 214585

#### DISPENSING RESTRICTIONS

N/A

### Overview

#### INDICATION FOR USE

Mesalamine extended-release capsules are indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis.

#### MECHANISMS OF ACTION

The mechanism of action of mesalamine (and sulfasalazine) is not fully understood, but it appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways (i.e., prostanoids) and through the lipoxygenase pathways (i.e., leukotrienes (LTs)) and hydroxyeicosatetraenoic acids (HETEs), is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.

#### DOSE FORM AND STRENGTH

Mesalamine 500mg extended-release capsules

#### DOSE & ADMINISTRATION

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## FIRST TIME GENERIC APPROVAL

The recommended dosage for the induction of remission and the symptomatic treatment of mildly to moderately active ulcerative colitis in adults is 1 g (2 mesalamine extended-release 500-mg capsules) 4 times a day for a total daily dosage of 4 g. Treatment duration in controlled trials was up to 8 weeks.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.